Wei Lishuang, Xie Hailun, Yan Ping
Geriatric Respiratory Disease Ward, The First Affiliated Hospital of Guangxi Medical University.
Department of Colorectal and Anal Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, PR China.
Medicine (Baltimore). 2020 Dec 11;99(50):e23486. doi: 10.1097/MD.0000000000023486.
This meta-analysis aimed to evaluate the prognostic value of the systemic inflammation response index (SIRI) in malignancy based on existing evidence.
We searched for relevant literature published in the electronic databases PubMed, Web of Science, Cochrane Library, and Embase before April 10, 2020. Hazard ratios (HR) and corresponding 95% confidence intervals (CI) were calculated and pooled to evaluate the relationship between SIRI and malignancy outcomes.
We included 14 articles, describing 6,035 patients. Our findings revealed that patients with high SIRI had worse overall survival (OS) (HR = 2.20, 95% CI: 1.85-2.62, P < .001), disease-free survival (DFS) (HR: 1.92, 95% CI: 1.49-2.48, P < .001), time-to-progression (TTP) (HR: 2.00, 95% CI: 1.55-2.58, P < .001), progression-free survival (PFS) (HR: 1.73, 95% CI: 1.38-2.16, P < .001), cancer-specific survival (CSS) (HR: 3.57, 95% CI: 2.25-5.68, P < 0.001), disease-specific survival (DSS) (HR: 1.99, 95% CI: 1.46 - 2.72, P < .001), and metastasis-free survival (MFS) (HR: 2.26, 95% CI: 1.28-3.99, P = .005) than patients with low SIRI. The correlation between SIRI and OS did not change in a subgroup analysis. Meta-regression indicated that heterogeneity may be related to differences in primary therapy strategies. Sensitivity analysis suggested that our results were reliable.
SIRI could be used as a useful predictor of poor prognosis during malignancy treatment.
本荟萃分析旨在基于现有证据评估全身炎症反应指数（SIRI）在恶性肿瘤中的预后价值。
我们检索了2020年4月10日前在电子数据库PubMed、科学网、Cochrane图书馆和Embase上发表的相关文献。计算并汇总风险比（HR）及相应的95%置信区间（CI），以评估SIRI与恶性肿瘤预后之间的关系。
我们纳入了14篇文章，共描述了6035例患者。我们的研究结果显示，与SIRI低的患者相比，SIRI高的患者总生存期（OS）更差（HR = 2.20，95% CI：1.85 - 2.62，P <.001）、无病生存期（DFS）更差（HR：1.92，95% CI：1.49 - 2.48，P <.001）、疾病进展时间（TTP）更差（HR：2.00，95% CI：1.55 - 2.58，P <.001）、无进展生存期（PFS）更差（HR：1.73，95% CI：1.38 - 2.16，P <.001）、癌症特异性生存期（CSS）更差（HR：3.57，95% CI：2.25 - 5.68，P < 0.001）、疾病特异性生存期（DSS）更差（HR：1.99，95% CI：1.46 - 2.72，P <.001）以及无转移生存期（MFS）更差（HR：2.26，95% CI：1.28 - 3.99，P =.005）。亚组分析中SIRI与OS之间的相关性未发生变化。Meta回归表明异质性可能与初始治疗策略的差异有关。敏感性分析表明我们的结果是可靠的。
SIRI可作为恶性肿瘤治疗期间预后不良的有用预测指标。
